What was known before {#section17-2054358118774537}
=====================

Polycystic kidney disease (PKD) is associated with progressive, incurable chronic kidney disease (CKD). Whether the risk of complications (end-stage kidney disease \[ESKD\], cardiac disease, infection, and death) related to CKD are similar in patients with PKD to without PKD is unknown.

What this adds {#section18-2054358118774537}
==============

Patients with PKD and advanced CKD in Canada have a higher risk of ESKD and cardiac events and comparable risks of infections and death compared with similar patients without PKD.

Introduction {#section19-2054358118774537}
============

Polycystic kidney disease is a commonly inherited disorder resulting in kidney disease, affecting roughly 1:1000 to 1:400 people worldwide.^[@bibr1-2054358118774537]^ Polycystic kidney disease leads to a progressive, often predictable decline in kidney function over decades, ultimately resulting in ESKD.^[@bibr2-2054358118774537]^ As such, patients with PKD may experience long periods of time with nondialysis-dependent CKD.^[@bibr3-2054358118774537]^ Despite this, the majority of research has focused on PKD-related complications such as hematuria, pain, abdominal distension, and hypertension.^[@bibr4-2054358118774537]^ Conversely, the risks of well-established CKD complications such as cardiac disease and infections are not as well known.

Chronic kidney disease--related adverse outcomes are well established; these include, but are not limited to, infection, ischemic heart disease, congestive heart failure (CHF), CKD progression, and death.^[@bibr5-2054358118774537][@bibr6-2054358118774537][@bibr7-2054358118774537]-[@bibr8-2054358118774537]^ Chronic kidney disease--related adverse outcomes confer a significant increase in the risk of mortality and morbidity in patients with ESKD, regardless of the etiology.^[@bibr9-2054358118774537][@bibr10-2054358118774537]-[@bibr11-2054358118774537]^ However, not all patients with CKD appear to be at a similar risk of developing these adverse outcomes. As patients with PKD are often younger with fewer comorbid illnesses than other patients with CKD, it follows that their subsequent risk of adverse outcomes, including ESKD, may differ compared with that of patients with CKD due to other etiologies. Better characterization of these risks in patients with PKD could aid in determining appropriate monitoring and identifying potentially modifiable risk factors to reduce these risks and their burden to patients, families, and the health care system.

In this study, using the Canadian study of Prediction of Death, Dialysis and Interim Cardiovascular events (CanPREDDICT) prospective cohort, we set out to examine the risk of adverse outcomes of patients with PKD and advanced CKD relative to those with advanced CKD and without PKD. We hypothesized that for patients with PKD, the risk of adverse cardiac events, infections, and all-cause mortality would be lower, but the risk of ESKD would be higher, relative to those with CKD and without PKD.

Materials and Methods {#section20-2054358118774537}
=====================

Participants {#section21-2054358118774537}
------------

In this study, we used data from the CanPREDDICT prospective cohort study.^[@bibr12-2054358118774537]^ CanPREDDICT was a multicenter observational study of non-dialysis CKD patients cared for by nephrologists across Canada from 2008-2009. Patients were followed for 3 years at 6-month intervals then annually up to 5 years. Inclusion criteria were patients with an estimated glomerular filtration rate (eGFR) 15 to 45 mL/min/1.73 m^2^. Patients were excluded if they had a functioning kidney or other solid organ transplant, acute vasculitis requiring immunosuppressive therapy, or a life expectancy of less than 6 months. The full study description with enrollment criteria and baseline characteristics has previously been described.^[@bibr13-2054358118774537]^ All study participants gave signed consent and regional ethics board approval was granted by the Ottawa Hospital.

Sociodemographic, clinical, and laboratory data were collected at the initial visit. These included sex, age (years), ethnicity, presence of diabetes, as well as cardiac, cerebrovascular, and peripheral vascular disease. Laboratory parameters recorded at baseline included serum eGFR (mL/min/1.73 m^2^ by Modification of Diet in Renal Disease (MDRD)), serum phosphate (mEQ/L), albumin (g/L), and urine albumin to creatinine ratio (ACR) (mg/mmol).^[@bibr14-2054358118774537]^

Exposure {#section22-2054358118774537}
--------

The exposure of interest was PKD as identified by the treating physician.

Study Outcomes {#section23-2054358118774537}
--------------

Adjudicated study outcomes were cardiac ischemia, CHF, ESKD, and mortality. Exact dates of the outcomes were available. Cardiac ischemia was defined as fatal or non-fatal myocardial infarction (MI), need for coronary revascularization (coronary artery bypass graft or percutaneous coronary intervention or percutaneous transluminal coronary angioplasty), and unstable angina (chest pain and absence of infarction shown on electrocardiogram \[ECG\], dynamic troponin or creatine kinase changes, or treatment with intravenous heparin). Congestive heart failure was defined as dyspnea plus 2 of the following: bibasilar rales, raised jugular venous pressure, or chest x-ray with evidence of interstitial or alveolar pulmonary edema. A panel of 3 physicians comprising a nephrologist, a cardiologist, and a neurologist independently adjudicated all cardiac outcomes based on source documentation. End-stage kidney disease initiation date was recorded at 3 months after commencing renal replacement therapy (RRT) (except in patients who suffered a death, who received a transplant \<3 months of initiation of RRT, or were on their final visit) to avoid misclassification of transient dialysis use followed by recovery. Deaths were included if they occurred \<3 months after commencing ESKD. The criteria of an infectious episode included one of the following: (1) positive culture, (2) prescription of antibiotics, or (3) requiring hospitalization for infection. Infections were classified by anatomical location as respiratory, urinary, bacteremia (blood culture positive), and other (including those whose anatomical location was not clear).

We censored all patients following an organ transplant, who were lost to follow-up, who withdrew from the study, and at the onset of ESKD. If no event occurred, the last visit date was taken as the end date. For patients who withdrew or were lost to follow-up, the previous visit date was taken as the censoring date.

Statistical Analyses {#section24-2054358118774537}
--------------------

We used standardized differences to assess differences in baseline characteristics between patients with CKD by PKD status. Standardized differences describe differences between group means relative to the pooled standard deviation and are less sensitive to large sample sizes than traditional hypothesis testing.^[@bibr15-2054358118774537]^ A difference of \>10% was considered meaningful. We used propensity score (PS) matching followed by Cox proportional hazards model to examine the association of PKD and the outcomes of interest.^[@bibr16-2054358118774537]^ The following variables were included in the PS model: age (per year), sex, comorbidities at baseline (diabetes, MI, coronary artery disease, peripheral vascular disease), laboratory values (eGFR, phosphate, albumin, urine ACR), systolic and diastolic blood pressure (BP), and medications (antiplatelet agents, statins, beta-blockers, angiotensin converting enzyme \[ACE\] inhibitors, angiotensin receptor blockers \[ARB\]). Patients with PKD were matched with no replacement 1:4 to patients without PKD on the logit of the PS (caliper of 0.01).

The association of PKD and each outcome of interest were examined by Cox proportional hazards models. The date of the first study visit was used as start of the follow-up time and the time to first outcome (cardiac, infection, ESKD) was modeled. Models accounted for clustering due to matching.^[@bibr17-2054358118774537]^ In a sensitivity analysis, imbalanced covariates with standardized differences \>0.10 post--PS match (diastolic BP, acetylsalicylic acid \[ASA\], ACE inhibitor, ARB; see [Table 1](#table1-2054358118774537){ref-type="table"}) were added to the model. All statistical analyses were performed using SAS v9.4. A *P* value of \< .05 was considered significant.

###### 

Baseline Characteristics of Patients With PKD Compared With Those Without for the Total Cohort and PS-Matched Cohort.

![](10.1177_2054358118774537-table1)

  Variable                              Total cohort   SDiff          PS matched     SDiff                                    
  ------------------------------------- -------------- -------------- -------------- ---------- -------------- -------------- ----------
  N                                     2370           105 (4.4)      2265 (95.6)               105            416            
  Age (years, SD)                       68 (13)        62.7 (13.0)    68.3 (12.6)    **0.43**   62.7 (13.0)    62.5 (14.7)    0.02
  Sex, n (% male)                       1477 (62)      60 (57.1)      1417 (62.6)    **0.11**   60 (57.1)      233 (56.0)     0.02
  Race, n (% Caucasian)                 2108 (89)      92 (87.6)      2016 (89.0)    0.04       92 (87.6)      365 (87.7)     0.00
  Cause of CKD                                                                                                                
   Diabetes, n (%)                                                    673 (29.7)                               40 (9.6)       
   Ischemia, n (%)                                                    610 (26.9)                               106 (25.5)     
   Glomerulonephritis, n (%)                                          273 (12.1)                               98 (23.6)      
   Pyelonephritis/interstitial, n (%)                                 107 (4.7)                                33 (7.9)       
   Other, n (%)                                                       281 (12.4)                               71 (17.1)      
   Unknown, n (%)                                                     321 (14.2)                               68 (16.3)      
   Diabetes, n (%)                      1133 (48%)     15 (14.3)      1118 (49.4)    **0.81**   15 (14.3)      66 (15.9)      0.04
   Cardiovascular disease, n (%)        1055 (44%)     22 (21.0)      1033 (45.6)    **0.37**   22 (21.0)      114 (27.4)     0.04
   Ischemic, n (%)                      784 (33%)      18 (17.1)      766 (33.8)     **0.39**   18 (17.1)      83 (20.0)      0.07
   Congestive heart failure, n (%)      617 (26%)      13 (12.4)      604 (26.7)     **0.37**   13 (12.4)      57 (13.7)      0.04
   Peripheral vascular disease, n (%)   464 (20%)      14 (13.3)      450 (19.9)     **0.37**   14 (13.3)      50 (12.0)      0.04
   No. of comorbidities (SD)            1.1 (1.4)      0.4 (1.0)      1.1 (1.4)      **0.58**   0.4 (1.0)      0.5 (1.0)      0.07
   eGFR in mL/min per 1.73 m^2^ (SD)    28.2 (9)       27.3 (9.0)     28.2 (9.0)     **0.11**   27.3 (9.0)     28.0 (9.0)     0.08
   Albumin in g/L (SD)                  40.0 (4)       41.2 (3.5)     40.4 (4.2)     **0.19**   41.2 (3.5)     41.5 (4.0)     0.09
   Urine ACR in mg/mmol (IQR)           79.1 (153.4)   44.5 (80.5)    80.7 (155.8)   **0.29**   44.5 (80.5)    38.3 (83.7)    0.08
   Systolic BP in mm Hg (SD)            133.7 (19.7)   128.3 (16.1)   134.0 (19.8)   **0.31**   128.3 (16.1)   129.9 (18.0)   0.09
   Diastolic BP in mm Hg (SD)           71.0 (11.8)    74.0 (11.8)    70.9 (11.8)    **0.27**   74.0 (11.8)    74.0 (10.9)    **0.12**
  Medications                                                                                                                 
   ASA, n (%)                           1272 (53.7)    36 (34.3)      1276 (54.6)    **0.42**   36 (34.3)      36 (40.9)      **0.14**
   ACE inhibitors, n (%)                1058 (44.6)    49 (46.7)      44.5 (53.0)    **0.42**   49 (46.7)      175 (42.1)     **0.14**
   ARB, n (%)                           882 (37.2)     29 (27.6)      853 (37.7)     **0.22**   29 (27.6)      142 (34.1)     **0.14**
   Beta-blocker, n (%)                  1082 (45.7)    38 (36.2)      1044 (46.1)    **0.20**   38 (36.2)      141 (33.9)     0.05
   Statin, n (%)                        1598 (67.4)    58 (55.2)      1540 (68.0)    **0.26**   58 (55.2)      243 (58.4)     0.06

*Note.* Bold *P* values denote statistically significant standardized differences (SDiff \> 0.2). PKD = polycystic kidney disease; SDiff = standardized difference; PS matched = propensity score matched; eGFR = estimated glomerular filtration rate; ACR = albumin to creatinine ratio; IQR = interquartile range; BP = blood pressure; ASA = acetylsalicylic acid; ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blocker.

Results {#section25-2054358118774537}
=======

Based on inclusion and exclusion criteria, the study cohort consisted of 105 patients with PKD and 2265 without PKD. The analytic cohort consisted of 105 patients with PKD and 416 without PKD who were PS-matched (1:4). There were 4 patients with PKD for whom only 3, rather than 4, matches were identified. The median and total follow-up times were 3.8 (interquartile range \[IQR\]: 2.7-4.0) and 1680 years, respectively.

Baseline characteristics of the study cohort included in this study are depicted in [Table 1](#table1-2054358118774537){ref-type="table"}. Prior to PS matching, there were statistically significant differences across all covariates except for race. The PKD group was younger (63 vs 68 years old), with a lower proportion of diabetes (14% vs 49%), cardiovascular disease (21 vs 45.6), peripheral vascular disease (13.3% vs 19.9%), and fewer total mean comorbidities (0.4 vs 1.1). Serum albumin (mean 41.2 vs 40.4) and diastolic BP (74 vs 70.9) were higher in the PKD group, whereas urine ACR (44.5 vs 80.7) and systolic BP (128.3 vs 134) were lower. There was lower use of all medications in the PKD group. After PS matching, there was no statistically significant difference between the age (62.7 vs 62.5), diabetes (14.3 vs 15.9%), cardiac disease (21 vs 27.4), peripheral vascular disease (13.3 vs 12%), and number of comorbidities (0.4 vs 0.5). Similarly, serum albumin, urine ACR ratio, systolic BP, as well as beta-blocker and statin usage were similar between the groups. Standardized differences greater than 0.10 persisted for diastolic BP (11.8 vs 10.9, SD = 0.12), ASA use (34.3 vs 40.9 SD = 0.14), ACE inhibitors (46.7 vs 42.1%, SD = 0.14), and ARB (27.6 vs 34.1%, SD = 0.14).

During the study period, 25.7% (n = 27) of patients with PKD developed ESKD as compared with 13.5% (n = 56) of patients without PKD ([Figure 1](#fig1-2054358118774537){ref-type="fig"}). For patients with PKD, 9.5% had any cardiac event (8.6% \[n = 9\] cardiac ischemia and 2.9% \[n = 3\] CHF). For patients without PKD, 7.9% experienced a cardiac event (5.5% \[n = 23\] cardiac ischemia and 3.6% \[n = 15\] CHF). In total, the all-cause mortality was 6.7% of patients with PKD (n = 7 from 105 total) versus 7.7% for those without PKD patients (n = 32 from 416 total). In time to event analyses, PKD was independently associated with ESKD (hazard ratio \[HR\] = 2.00, 95% confidence interval \[CI\] = 1.33-3.01) and any cardiac event (HR = 1.46, 95% CI = 1.04-2.04). Any infection (HR = 1.16, 95% CI = 0.75-1.82), cardiac ischemia (HR = 1.18, 95% CI = 0.67-2.09), CHF (HR = 0.85, 95% CI = 0.41-1.75), and all-cause mortality (HR = 0.87, 95% CI = 0.40-1.91) were similar between the 2 groups (see [Figure 2](#fig2-2054358118774537){ref-type="fig"}). These findings were consistent in a sensitivity analysis with adjusting for imbalance post--PS match (Supplementary Table 1).

![Proportion of clinical outcomes in CKD patients with PKD compared with those without.\
*Note.* CKD = chronic kidney disease; PKD = polycystic kidney disease; ESKD = end-stage kidney disease; CHF = congestive heart failure.](10.1177_2054358118774537-fig1){#fig1-2054358118774537}

![Proportion of types of infections in CKD patients with PKD compared with those without.\
*Note.* CKD = chronic kidney disease; PKD = polycystic kidney disease.](10.1177_2054358118774537-fig2){#fig2-2054358118774537}

A comparison of the proportions of infection types are presented in [Figure 3](#fig3-2054358118774537){ref-type="fig"}. Twelve patients with PKD experienced a urinary tract infection (UTI) (52.2% of total PKD infections) and 8 experienced pneumonia (34.8%). Of the 23 patients with PKD, 1 developed bacteremia. For those without PKD, 43.6% developed a UTI, 29.8% pneumonia, and 6.4% bacteremia. Other infections (non-UTI/bacteremia/pneumonia) affected 8.7% of patients with PKD (n = 2) and 20.2% of those without PKD (n = 19). There were no statistically significant differences between the 2 groups for infection types.

![Propensity score matched hazard ratio (95% confidence interval) of clinical outcomes among patients with PKD (Non-PKD referent).\
*Note.* PKD = polycystic kidney disease; HR = hazard ratio; n = number of events; ESKD = end-stage kidney disease; CHF = congestive heart failure.](10.1177_2054358118774537-fig3){#fig3-2054358118774537}

Discussion {#section26-2054358118774537}
==========

In this national prospective cohort study of patients with advanced CKD being followed by a nephrologist (CanPREDDICT), we found key differences in the risks of adverse outcomes for those with PKD. After matching for a broad number of covariates, we demonstrated a higher risk of ESKD, and a comparable risk of cardiovascular events, infections, and all-cause mortality. There were no apparent differences in the types of infections that occurred. Surprisingly, the composite outcome of cardiac events (ischemic events and CHF exacerbations) was higher in patients with PKD (HR = 1.46, 95% CI = 1.04-2.04) albeit with a small number of overall events. Overall, our findings illustrate that non-ESKD adverse events are comparable between patients with advanced CKD with and without PKD.

Although patients with PKD are often younger with fewer comorbid illnesses, we observed an increased risk of cardiac events in patients with PKD compared with those without. This is consistent with evidence suggesting patients with PKD are predisposed to developing coronary artery disease, valvular heart disease, and cardiomyopathies.^[@bibr18-2054358118774537]^ Chapman et al reported the presence of left ventricular hypertrophy in 36% of patients with PKD compared with general population controls.^[@bibr19-2054358118774537]^ In a self-reported survey study with a low response rate, Helal et al found cardiovascular disease was highly prevalent in PKD with the most common causes being arrhythmia (25.9%), peripheral vascular disease (16.5%), valvular heart disease (14.4%), and MI (6%).^[@bibr20-2054358118774537]^ In an autopsy study consisting mostly of patients with PKD who had ESKD (77%), cardiac hypertrophy was present in 89% and coronary artery disease in 81%. Recently, in a small series of patients with PKD with echocardiographic data, idiopathic dilated cardiomyopathy was observed in 5.8% and hypertrophic obstructive cardiomyopathy in 2.5%.^[@bibr21-2054358118774537]^ On dialysis, cardiac causes are the most common cause of death for both patients with and without PKD; however, cardiac mortality has been reported to be declining steadily among those with PKD.^[@bibr22-2054358118774537]^ Our findings further support the notion that patients with PKD may be at a particularly increased risk of cardiac events compared with those with CKD due to other etiologies.

As cardiac complications are emerging as a major cause of morbidity and mortality in patients with PKD, aggressive treatment of hypertension, early diagnosis, and clinical intervention for such risks are beneficial. Early detection of hypertension may play a role as its onset precedes the loss of kidney function in the majority of patients with PKD.^[@bibr23-2054358118774537]^ The role of screening echocardiography and ECG early in the course of disease and serially needs to be defined through further study. Finally, the role of prophylactic cardiovascular medications may offset the burden of cardiac disease. Patients with PKD in our cohort were less likely to be on ASA, ARB, and/or statins post-match suggesting the risk of cardiac disease may be under recognized by physicians.

The development of ESKD is a significant and predictable complication of PKD.^[@bibr3-2054358118774537],[@bibr24-2054358118774537],[@bibr25-2054358118774537]^ Hateboer et al investigated the difference between the age of onset of ESKD or death in ADPKD individuals with PKD1 or PKD2 mutations as compared with healthy family members (controls).^[@bibr26-2054358118774537]^ The median age at death or onset of ESKD was 53.0 years in individuals with PKD1 (35% of their cohort), 69.1 years in those with PKD2 (14%), and 78.0 years in controls. Recent reports suggest a higher prevalence of ESKD among patients with PKD compared with our cohort of 21.9%. Possibilities for this discrepancy include shorter follow-up time of the CanPREDDICT cohort study (5 years) or the inclusion of patients with less severe types of PKD.^[@bibr22-2054358118774537],[@bibr27-2054358118774537]^

Kidney infection is a common reported occurrence in PKD (30%-50% lifetime risk) and often leads to serious complications, including perinephric abscess, acute kidney injury (AKI), septicemia, and death.^[@bibr28-2054358118774537][@bibr29-2054358118774537]-[@bibr30-2054358118774537]^ Hwang et al examined 49 patients with ADPKD (19 men and 30 women) and reported the occurrences of UTI as 26% in PKD compared with 0% in healthy controls. Interestingly, we did not find any difference in the risk or type of infections in our study population as compared with other patients with non-PKD. We previously reported that infectious episodes in CKD were common and conferred a high risk of subsequent adverse outcomes.^[@bibr6-2054358118774537]^ Possible reasons for the lack of difference observed in our study include the limited number of infectious episodes and its subtypes. In summary, while the outcomes of infections in patients with PKD may be more deleterious, we did not find any difference in the overall incidence of infections in patients with CKD with or without PKD.

We found no difference in all-cause mortality between the 2 groups. To date, there are few reports investigating mortality in patients with PKD and CKD. A study from Taiwan analyzed an adult cohort of PS matched 1:3 patients with ESKD due to ADPKD compared with those with non-ADPKD.^[@bibr31-2054358118774537]^ The aim of this study was to compare the outcomes between patients on peritoneal dialysis (PD) with ADPKD and without ADPKD. They found no difference in overall mortality. Peritoneal dialysis patients with ADPKD were found to be comparable with PD patients without ADPKD in terms of risk of death and hospitalization in the present study. In another study that looked at 501 Taiwanese patients, there was no significant difference found in survival rates between patients with ESKD with and without ADPKCD.^[@bibr32-2054358118774537]^ While there is a lower incidence of ADPKD in Taiwan compared to North America, these 2 studies do support our findings that there is no difference in all-cause mortality between patients with CKD with and without ADPKD.

Limitations of our study include the small number of events in certain categories, the inability to distinguish types of PKD, and the lack of other relevant PKD-related outcomes such as hematuria or pain. Although our PS-matched groups were well balanced, there is the possibility of residual confounding as important variables such as functional status and eGFR changes over time were not captured. Although we had access to a large Canadian cohort of CKD patients with PKD, the absolute numbers of patients in each outcome group was small, making statistical significance of our findings limited. Despite this limitation, as the outcomes were adjudicated, we are confident in their accuracy. We were not able to determine the severity of an infection or cardiac event. ESKD outcomes did not include patients conservatively managed for ESKD as opposed to initiating dialysis; thus, we have also technically underestimated the number of patients in whom ESKD developed and this may have differed between patients with PKD and those without. Future studies involving more patients will be needed to confirm our findings. Other limitations of our study were related to our study design being a prospective observational (cohort) analysis: there was the potential for selection bias and incomplete data collection.

In conclusion, in a large, prospective cohort of patients with PKD and advanced CKD, we found a higher risk of ESKD and cardiac events and similar risk of all-cause mortality and infection risk between matched patients. Future areas of research should focus on validating these results in other cohorts. Our findings underscore the high risk of cardiac events in patients with PKD. These findings are particularly surprising in the context of the current recommendations for aggressive BP reduction in patients with PKD using ACE inhibitors as first line therapy. Further research is needed to understand the pathophysiological underpinnings of this association. In addition, our findings suggest that an increased emphasis on the prevention, monitoring, and treatment of cardiac disease in patients with PKD may be warranted.
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